Effects of SDF-1α, anti–SDF-1α, or anti-CXCR4 treatment on human thymocyte development in chimeric human-mouse FTOC
| Treatment . | Length of culture . | |
|---|---|---|
| 10 d . | 18 d . | |
| Control | 26 677 ± 3 496* | 29 348 ± 4 002 |
| IgG2a | Not determined | 27 830 ± 4 453 |
| SDF-1α | 100 600 ± 13 294 | 95 312 ± 7 539 |
| Antihuman CXCR4 | 4 291 ± 750 | 5 932 ± 899 |
| Antihuman SDF-1α | 9 576 ± 1 524 | 7 997 ± 1 039 |
| Treatment . | Length of culture . | |
|---|---|---|
| 10 d . | 18 d . | |
| Control | 26 677 ± 3 496* | 29 348 ± 4 002 |
| IgG2a | Not determined | 27 830 ± 4 453 |
| SDF-1α | 100 600 ± 13 294 | 95 312 ± 7 539 |
| Antihuman CXCR4 | 4 291 ± 750 | 5 932 ± 899 |
| Antihuman SDF-1α | 9 576 ± 1 524 | 7 997 ± 1 039 |
Number of human cells was calculated by multiplying the total number of cells by the percentage of human CD45+ cells determined by flow cytometry analysis. The data represent the mean ±SD from 3 to 8 independent experiments wherein a pool of at least 5 thymic lobes per test were analyzed. Differences between cell numbers in control and rhSDF-1α–, antihuman SDF-1α–, or antihuman CXCR4–treated FTOC were statistically significant, with P≤ .05 for 10 and 18 days of culture.